title: Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma.
abstract: Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) with the monoclonal antibody mAb9.2.27 and activated natural killer (NK) cells abrogated the tumor growth and prolonged the survival of glioblastoma-bearing animals by favoring the establishment of a pro-inflammatory microenvironment. The combination of NK cells and mAb9.2.27 recruited ED1+CCR2lowmacrophages that stimulated ED1+ED2lowMHCIIhighmicroglial cells to exert robust cytotoxicity. Our findings demonstrate the therapeutic potential of targeting salient tumor associated-antigens.
authors.affiliation: University of Bergen; Institute for Biomedicine; Bergen, Norway.
authors.forename: Justyna
authors.initials: J
authors.lastname: Kmiecik
authors.affiliation: University of Bergen; Institute for Biomedicine; Bergen, Norway.
authors.forename: Andrea
authors.initials: A
authors.lastname: Gras Navarro
authors.affiliation: Laboratoire d'Immunogénétique-Allergologie; CRP-Santé, Luxembourg.
authors.forename: Aurelie
authors.initials: A
authors.lastname: Poli
authors.affiliation: Department of Neuroimmunology; Hospital Clinic (IDIBAPS); Barcelona, Spain.
authors.forename: Jesús Planagumà
authors.initials: JP
authors.lastname: Planagumà
authors.affiliation: Laboratoire d'Immunogénétique-Allergologie; CRP-Santé, Luxembourg.
authors.forename: Jacques
authors.initials: J
authors.lastname: Zimmer
authors.affiliation: University of Bergen; Institute for Biomedicine; Bergen, Norway ; University of Bergen, Institute for Clinical Dentistry; Bergen, Norway.
authors.forename: Martha
authors.initials: M
authors.lastname: Chekenya
keywords: CNS immunosurveillance; CSPG4; NK cells; glioblastoma; passive immunotherapy